China cracks down on the manufacture and sale of fake and substandard new crown treatment drugs Wuhan offers virus antibody testing services

Read Time:4 Minute, 38 Second

Since the implementation of the “Class B” control of NIC, Chinese officials have continued to promote the research and development and marketing of NIC drugs and cracked down on the production and sale of counterfeit and substandard NIC drugs; local governments have further optimized their NIC medical insurance reimbursement policies and provided NIC antibody tests to meet the public’s medical needs and ensure the quality and safety of medication. The quality and safety of drugs.

A new coronary serious illness treatment drugs approved official crackdown on the sale of counterfeit and substandard drugs illegal criminal behavior

According to the State Drug Administration on the 16th news, recently, the State Drug Administration approved the tolzumab injection (trade name: Schreli) declared by Biotest Biopharmaceutical Co. The drug is the first tolimumab injection biosimilar approved in China.

It is reported that at present, tolimumab injection is included in the “Novel Coronavirus Infection Treatment Plan (Trial 10th Edition)” and “Novel Coronavirus Infection Treatment Plan for Severe Cases (Trial 4th Edition)”, which can be tried for severe cases with significantly elevated IL-6 levels in laboratory tests.

In addition, in response to the recent clues of illegal sales of new coronavirus infection treatment drugs of unknown origin in the market, local drug regulatory authorities, together with local public security departments, have jointly enforced the law and dismantled some criminal gangs and dens, and seized a batch of counterfeit Paxlovid (nematovir tablets/ritonavir tablets combination package) and unapproved imported drugs during the net closing operation.

Upon inspection, some of the seized products did not contain effective pharmaceutical ingredients or illegally added other pharmaceutical ingredients, and were suspected of violating Article 141 of the Criminal Law for the crime of selling counterfeit drugs. At present, the case is being handled by the public security department in accordance with the law.

Shenzhen to implement the new crown patients hospitalization costs of full coverage Wuhan to provide new crown virus antibody test

Shenzhen Medical Security Bureau recently issued a notice to optimize the medical security policies related to the treatment costs of patients with new coronavirus infection. This includes the implementation of full coverage of hospitalization costs for patients with neo-coronavirus infection, which is calculated on the basis of the admission time of patients with neo-coronavirus infection and implemented first until March 31, 2023.

From January 8 to March 31, patients with NIV and suspected symptoms will be reimbursed 85% of the medical expenses related to the treatment of NIV within the scope of the medical insurance catalog in outpatient and emergency clinics of designated medical institutions at the second level or below, with no starting line and no ceiling line. The out-of-pocket expenses can be paid by the balance of the participant’s personal account according to the regulations.

Wuhan CDC preventive medicine service center recently launched the new crown virus nucleic acid antibody level testing service, for the public scientific assessment of the new crown rehabilitation immune status and resistance to secondary infection. The Wuhan CDC said that the new coronavirus antibody test can be used as a basis for the auxiliary diagnosis of new coronavirus infection, and can also be used as a basis for the recommendation of new coronavirus vaccination schedule and vaccination protocol.

With the global New Coronavirus epidemic entering the normal prevention and control stage, many countries require a negative Nucleic Acid Test Report for New Coronavirus at the immigration office, and the English version of the Nucleic Acid Test Report for New Coronavirus has become one of the necessary and effective credentials for immigration and visa. In order to meet the needs of the public to study abroad, business, visiting relatives, immigration and tourism, Wuhan CDC Preventive Medicine Service Center also provides the English and Chinese versions of the nucleic acid test reports to the public in need.

Since January 8, the national immigration management agencies daily average inspection of 501,000 people entering and leaving the country

According to the National Immigration Administration on January 17, since January 8, 2023, the official implementation of the new coronavirus infection “Category B B control”, the national immigration authorities daily average inspection of immigration personnel 501,000, compared with the implementation of 48.2%, 26.3% of the pre-epidemic; the average daily acceptance of immigration documents 341,000, compared with the implementation of 129.4%, an increase of 129.4%. The average daily number of entry and exit documents accepted was 341,000, up 129.4% from the pre-implementation period and 54.5% from the pre-epidemic period.

Dr. Li Dong, chief physician of the Infectious Diseases Division at Beijing Youan Hospital, has suggested that travel abroad during the Spring Festival may encounter strains different from those in China, and that the risk of infection increases when traveling abroad if one has not had a “yang”. If you get sick in a foreign country, you should also consider medical care and medication, and be prepared with epidemic prevention supplies such as masks and disinfectant wipes, and it’s best to learn about the local medical process.

Recently, the report that the XAY.2 strain of Deltakron was detected abroad has attracted attention. Dong Li has said that at present, no XAY.2 strain has been found to be a major prevalent strain in a particular country or region, increasing the rate of serious illness. Theoretically, the characteristics of the recombinant virus may become more uncertain, once the epidemic, indicating that it has a stronger immune escape ability, but also need to continue to pay attention. (End)